Patents by Inventor Charles A. Flentge

Charles A. Flentge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE
    Publication number: 20240002349
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Application
    Filed: June 20, 2023
    Publication date: January 4, 2024
    Inventors: Michael E. BOZIK, Scott S. HARRIED, Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, Charles A. FLENTGE, David A. MARESKA, James S. HALE
  • Benzoimidazol-1,2-yl amides as Kv7 channel activators
    Patent number: 11834418
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: December 5, 2023
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Lynn Resnick, George T. Topalov, Justin K. Belardi, James S. Hale, Scott S. Harried, Charles A. Flentge, David A. Mareska
  • Anti-Viral Compounds
    Publication number: 20230285378
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: September 9, 2022
    Publication date: September 14, 2023
    Applicant: AbbVie Inc.
    Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Warren M. Kati, Tammie K. Jinkerson, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
  • Kv7 channel activators compositions and methods of use
    Patent number: 11724990
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: August 15, 2023
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Michael E. Bozik, Scott S. Harried, Lynn Resnick, George T. Topalov, Justin K. Belardi, Charles A. Flentge, David A. Mareska, James S. Hale
  • KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE
    Publication number: 20230000831
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Application
    Filed: January 7, 2022
    Publication date: January 5, 2023
    Inventors: Michael E. BOZIK, Scott S. HARRIED, Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, Charles A. FLENTGE, David A. MARESKA, James S. HALE
  • KV7 channel activators compositions and methods of use
    Patent number: 11261162
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: March 1, 2022
    Assignee: KNOPP BIOSCIENCES, LLC
    Inventors: Michael E. Bozik, Scott S. Harried, Lynn Resnick, George T. Topalov, Justin K. Belardi, Charles A. Flentge, David A. Mareska, James S. Hale
  • BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
    Publication number: 20210188782
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Inventors: Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, James S. HALE, Scott S. HARRIED, Charles A. FLENTGE, David A. MARESKA
  • KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE
    Publication number: 20210130299
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Application
    Filed: October 22, 2020
    Publication date: May 6, 2021
    Inventors: Michael E. BOZIK, Scott S. HARRIED, Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, Charles A. FLENTGE, David A. MARESKA, James S. HALE
  • Benzoimidazol-1,2-yl amides as Kv7 channel activators
    Patent number: 10906877
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: February 2, 2021
    Assignee: Knopp Biosciences LLC
    Inventors: Lynn Resnick, George T. Topalov, Justin K. Belardi, James S. Hale, Scott S. Harried, Charles A. Flentge, David A. Mareska
  • Kv7 channel activators compositions and methods of use
    Patent number: 10851067
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: December 1, 2020
    Assignee: Knopp Biosciences LLC
    Inventors: Michael E. Bozik, Scott S. Harried, Lynn Resnick, George T. Topalov, Justin K. Belardi, Charles A. Flentge, David A. Mareska, James S. Hale
  • BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
    Publication number: 20200062714
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Application
    Filed: October 31, 2017
    Publication date: February 27, 2020
    Inventors: Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, Charles A. FLENTGE, James S. HALE, David A. MARESKA
  • Imidazo[4,5-b]pyridin-2-yl amides as Kv7 channel activators
    Patent number: 10526328
    Abstract: Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: January 7, 2020
    Assignee: Knopp Biosciences LLC
    Inventors: Lynn Resnick, George T. Topalov, Charles A. Flentge, James S. Hale, David A. Mareska, Justin K. Belardi, Kai Zhang, Scott S. Harried
  • BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
    Publication number: 20200002292
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Application
    Filed: July 2, 2019
    Publication date: January 2, 2020
    Inventors: Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, James S. HALE, Scott S. HARRIED, Charles A. FLENTGE, David A. MARESKA
  • KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE
    Publication number: 20190284142
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Application
    Filed: March 19, 2019
    Publication date: September 19, 2019
    Inventors: Michael E. BOZIK, Scott S. HARRIED, Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, Charles A. FLENTGE, David A. MARESKA, James S. HALE
  • Benzoimidazol-1,2-yl amides as Kv7 channel activators
    Patent number: 10385025
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: August 20, 2019
    Assignee: Knopp Biosciences LLC
    Inventors: Lynn Resnick, George T. Topalov, Justin K. Belardi, James S. Hale, Scott S. Harried, Charles A. Flentge, David A. Mareska
  • Anti-Viral Compounds
    Publication number: 20190015402
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: July 23, 2018
    Publication date: January 17, 2019
    Applicant: AbbVie Inc.
    Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
  • IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS
    Publication number: 20190002464
    Abstract: Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.
    Type: Application
    Filed: September 7, 2018
    Publication date: January 3, 2019
    Inventors: Lynn RESNICK, George T. TOPALOV, Charles A. FLENTGE, James S. HALE, David A. MARESKA, Justin K. BELARDI, Kai ZHANG, Scott S. HARRIED
  • Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators
    Patent number: 10106536
    Abstract: Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: October 23, 2018
    Assignee: Knopp Biosciences LLC
    Inventors: Lynn Resnick, George T. Topalov, Charles A. Flentge, James S. Hale, David A. Mareska
  • Anti-viral compounds
    Patent number: 10039754
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: August 7, 2018
    Assignee: AbbVie Inc.
    Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
  • Anti-viral compounds
    Patent number: 10028937
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: July 24, 2018
    Assignee: AbbVie Inc.
    Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller